Osaka, Japan

Koji Ohmoto

This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Otsuka Pharmaceutical Company, Limited. Active years: 2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Koji Ohmoto. Retrieved from https://idiyas.com/inventor/koji-ohmoto

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2017

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Koji Ohmoto: Innovator in Injectable Formulations

Introduction

Koji Ohmoto is a prominent inventor based in Osaka, Japan. He is known for his significant contributions to the field of pharmaceutical formulations. His work focuses on developing innovative solutions for medical treatments, particularly in the area of kidney diseases.

Latest Patents

Ohmoto holds a patent for an "Injectable depot formulation comprising optically active tolvaptan and process of producing the same." This invention provides an injectable formulation that can be administered intramuscularly or subcutaneously. It is designed for the prevention or treatment of polycystic kidney disease. The formulation maintains a therapeutically effective blood concentration of tolvaptan for an extended period. The patent details a process for producing this formulation, which includes a particle containing optically active tolvaptan as the active ingredient and a pharmaceutically acceptable carrier for injection.

Career Highlights

Koji Ohmoto is associated with Otsuka Pharmaceutical Company, Limited, where he has made significant strides in pharmaceutical research and development. His work has contributed to advancements in treatment options for patients suffering from chronic conditions.

Collaborations

Ohmoto has collaborated with notable colleagues, including Daiki Kaneko and Takakuni Matsuda. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Koji Ohmoto's contributions to injectable formulations represent a significant advancement in the treatment of polycystic kidney disease. His innovative approach and dedication to research continue to impact the pharmaceutical industry positively.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…